Table IV. LOD and LOQ of anti-CSP mAbs interactions with CSP Ags.
Ag | Ab/Diluent | Specific Binding of Diluent Alone, Mean ± SD (nm), n = 12 | LLOD (nM) | LLOQ (nM) | Upper LOD/LOQ (nM) | ||
---|---|---|---|---|---|---|---|
Calculated | Observed | Calculated | Observed | ||||
PF16 | AB000236 | ||||||
In PBS | 0.0010 ± 0.0033 | 2.0 | 2.3 | 3.9 | 3.3 | 50.0 | |
In NHS | 0.0035 ± 0.0100 | 0.3 | 0.5 | 1.1 | 3.3 | 25.0 | |
NANP6 | AB000334 | ||||||
In PBS | −0.0045 ± 0.0019 | 0.8 | 0.7 | 1.6 | 1.3 | 100.0 | |
In NHS | −0.0440 ± 0.0158 | 0.6 | 0.3 | 1.0 | 3.3 | 50.0 | |
CSP-FL | AB000236 | ||||||
In PBS | 0.0001 ± 0.0025 | 0.5 | 0.4 | 0.9 | 1.1 | 25.0 | |
In NHS | −0.0261 ± 0.0049 | 0.007 | 0.4 | 0.04 | 3.3 | 13.3 | |
AB000334 | |||||||
In PBS | 0.0020 ± 0.0034 | 0.4 | 0.4 | 1.2 | 1.7 | 100.0 | |
In NHS | −0.0256 ± 0.0059 | 0.2 | 0.4 | 0.4 | 3.3 | 50.0 |